Tumor Biology

, Volume 37, Issue 3, pp 3425–3431 | Cite as

KLF2 is downregulated in pancreatic ductal adenocarcinoma and inhibits the growth and migration of cancer cells

Original Article

Abstract

Members of the Kruppel-like factor (KLF) family have been considered as the tumor suppressors for their inhibitory effects on cell proliferation. Dysregulation of KLF2, a member of KLF family, has been observed in various cancer types. However, its expression pattern and functions in the pancreatic ductal adenocarcinoma (PDAC) are unknown. In this study, we examined the expression of KLF2 in PDAC clinical samples and evaluated the functions of KLF2 in the progression of PDAC. KLF2 is shown to be downregulated in PDAC clinical samples and overexpression of KLF2 inhibits the growth, migration, and metastasis of PDAC cancer cells. KLF2 interacts with beta-catenin and negatively regulates the beta-catenin/TCF signaling. Taken together, this study suggests the suppressive functions of KLF2 in PDAC.

Keywords

PDAC KLF2 Beta-catenin/TCF signaling Cell growth and migration 

Notes

Acknowledgments

This work was supported by the findings from the National Natural Science Foundation of China (81272728), Shanghai municipal commission of health and family planning (201440338), Shanghai Minhang district commission of science and technology (2014 MW22), and Shanghai Minhang district commission of Science and Technology (2011MHZ06, 2011MHZ25).

Conflicts of interest

None

References

  1. 1.
    Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Kumaran S, Samantha KS, Halagowder D. Does beta-catenin cross-regulate NFkappaB signalling in pancreatic cancer and chronic pancreatitis? Pathobiology. 2015;82:28–35.CrossRefPubMedGoogle Scholar
  3. 3.
    Xu W, Wang Z, Zhang W, et al. Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/beta-catenin signaling pathway. Cancer Lett. 2015;356:613–27.CrossRefPubMedGoogle Scholar
  4. 4.
    Chiurillo MA. Role of the WNT/beta-catenin pathway in gastric cancer. An in-depth literature review. World J Exp Med. 2015;5:84–102.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Buttar NS, Fernandez-Zapico ME, Urrutia R. Key role of kruppel-like factor proteins in pancreatic cancer and other gastrointestinal neoplasias. Curr Opin Gastroenterol. 2006;22:505–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Turner J, Crossley M. Basic kruppel-like factor functions within a network of interacting haematopoietic transcription factors. Int J Biochem Cell Biol. 1999;31:1169–74.CrossRefPubMedGoogle Scholar
  7. 7.
    Gao Y, Ding Y, Chen H, Chen H, Zhou J. Targeting kruppel-like factor 5 (KLF5) for cancer therapy. Curr Top Med Chem. 2015;15:699–713.CrossRefPubMedGoogle Scholar
  8. 8.
    Lahiri SK, Zhao J. Kruppel-like factor 8 emerges as an important regulator of cancer. Am J Transl Res. 2012;4:357–63.PubMedPubMedCentralGoogle Scholar
  9. 9.
    DiFeo A, Narla G, Martignetti JA. Emerging roles of kruppel-like factor 6 and kruppel-like factor 6 splice variant 1 in ovarian cancer progression and treatment. Mt Sinai J Med. 2009;76:557–66. New York.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL. Genomic profiling of tumor initiating prostatospheres. BMC Genomics. 2010;11:324.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wang F, Zhu Y, Huang Y, et al. Transcriptional repression of WEE1 by kruppel-like factor 2 is involved in DNA damage-induced apoptosis. Oncogene. 2005;24:3875–85.CrossRefPubMedGoogle Scholar
  12. 12.
    Nie FQ, Sun M, Yang JS, et al. Long noncoding rna anril promotes non-small cell lung cancer cell proliferation and inhibits apoptosis by silencing KLF2 and p21 expression. Mol Cancer Ther. 2015;14:268–77.CrossRefPubMedGoogle Scholar
  13. 13.
    Xie P, Tang Y, Shen S, et al. Smurf1 ubiquitin ligase targets kruppel-like factor KLF2 for ubiquitination and degradation in human lung cancer H1299 cells. Biochem Biophys Res Commun. 2011;407:254–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Xu TP, Liu XX, Xia R, et al. SP1-induced upregulation of the long noncoding RNA TINCR regulates cell proliferation and apoptosis by affecting KLF2 mRNA stability in gastric cancer. Oncogene (E pubmed ahead of print). 2015.Google Scholar
  15. 15.
    Xia R, Jin FY, Lu K, et al. Suz12 promotes gastric cancer cell proliferation and metastasis by regulating KLF2 and e-cadherin. Tumour Biol (E pubmed ahead of print). 2015.Google Scholar
  16. 16.
    Yin L, Wang JP, Xu TP, et al. Downregulation of kruppel-like factor 2 is associated with poor prognosis for nonsmall-cell lung cancer. Tumour Biol. 2015;36:3075–84.CrossRefPubMedGoogle Scholar
  17. 17.
    Taniguchi H, Jacinto FV, Villanueva A, et al. Silencing of kruppel-like factor 2 by the histone methyltransferase ezh2 in human cancer. Oncogene. 2012;31:1988–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Wei Y, Chen G, You L, Zhao Y. Krupel-like factor 8 is a potential prognostic factor for pancreatic cancer. Chin Med J. 2014;127:856–9.PubMedGoogle Scholar
  19. 19.
    Chakroborty D, Sarkar C, Yu H, et al. Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A. 2011;108:20730–5.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Qiao F, Yao F, Chen L, et al. Kruppel-like factor 9 was down-regulated in esophageal squamous cell carcinoma and negatively regulated beta-catenin/TCF signaling. Molecular carcinogenesis (E pubmed ahead of print). 2015.Google Scholar
  21. 21.
    Evans PM, Chen X, Zhang W, Liu C. KLF4 interacts with beta-catenin/TCF4 and blocks p300/CBP recruitment by beta-catenin. Mol Cell Biol. 2010;30:372–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Zhang W, Chen X, Kato Y, et al. Novel cross talk of kruppel-like factor 4 and beta-catenin regulates normal intestinal homeostasis and tumor repression. Mol Cell Biol. 2006;26:2055–64.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Dexiang Zhang
    • 1
  • Yuedi Dai
    • 2
  • Yuankun Cai
    • 1
  • Tao Suo
    • 3
  • Han Liu
    • 3
  • Yueqi Wang
    • 3
  • Zhijian Cheng
    • 1
  • Houbao Liu
    • 3
  1. 1.General Surgery Department, The Fifth People’s Hospital of ShanghaiFudan UniversityShanghaiChina
  2. 2.Department of Medical OncologyCancer Hospital of Fudan UniversityShanghaiChina
  3. 3.General Surgery Department, Zhongshan Hospital, General Surgery InstituteFudan UniversityShanghaiChina

Personalised recommendations